Navigation Links
NIH-funded scientists identify potential malaria drug candidates
Date:11/17/2011

Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream. The study, which appears in the Nov. 18 issue of Science, was led by Elizabeth A. Winzeler, Ph.D., of the Scripps Research Institute in La Jolla, Calif., and was partially funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Caused by four related parasites in the genus Plasmodium, malaria is transmitted to humans via the bite of an infected mosquito. Once the bite occurs, the parasites travel to the liver, where they usually multiply rapidly for about a week without causing symptoms. Symptoms begin when the parasites spread from the liver to the rest of the body through the bloodstream. However, the parasites can lay dormant in the liver for periods ranging from several months to years before an infected person demonstrates symptoms.

Most of the malaria drugs currently in development target the symptomatic, blood stage of infection. To help achieve malaria eradication, however, a drug would ideally treat infection during both the liver and blood stages. Currently, the World Health Organization recommends only one treatment, primaquine, for the initial, liver stage of certain types of malaria infection; however, primaquine and related drugs can cause a dangerous blood disorder among patients with a genetic condition that is common in malaria-endemic regions of the world. Additionally, drug resistance has been reported, which amplifies the need to find new treatment alternatives.

By screening more than 4,000 chemical compounds that had previously shown activity against blood-stage Plasmodium, the investigators searched for a compound that would also inhibit liver-stage parasites and whose protein structure would allow the modification necessary for future drug development. They found that a group of three related compounds, known collectively as the imidazolopiperazine (IP) cluster, fit these criteria. In addition, strains of Plasmodium that had acquired resistance to other malaria drugs were susceptible to the IP cluster.

Using the IP cluster as a foundation, the researchers designed a drug candidate, GNF179, that reduced levels of one Plasmodium species by 99.7 percent and extended survival by an average of 19 days when tested in malaria-infected mice. By examining infected cells, the researchers confirmed that GNF179 was active in the liver stage of infection. The researchers note that while additional studies will be needed to fully understand the drug's mechanism of action and its specific targets within the liver, this study provides a potential starting point for developing new dual-stage antimalarial drugs.


'/>"/>

Contact: Nalini Padmanabhan
padmanabhannm@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIH-funded scientists find 2009 H1N1 pandemic influenza vaccine protects mice from 1918 flu virus
2. University of Mississippi Medical Center to lead in nationwide NIH-funded Alzheimers study
3. NIH-funded study finds early HAART during TB treatment boosts survival rate in co-infected people
4. In NIH-funded study, researchers uncover step in brain events leading up to addiction
5. NIH-funded study uses new technology to peek deep into the brain
6. NIH-funded study finds new possible risk factor of heart disease
7. NIH-funded researchers find new ways to confuse blood-seeking mosquitoes
8. Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
9. NIH-funded research points to potential therapy for tumor-associated epilepsy
10. NIH-funded twin study finds occupational chemical exposure may be linked to Parkinsons risk
11. Scientists Pinpoint Area of Brain That Fears Losing Money
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their ... Eyeglasses . , Millions of individuals in the United States and Canada wear eyeglasses. ... way to both correct vision and make a fashion statement. Even celebrities use glasses ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: